Scancell shares rise 6% as melanoma trial progresses with new dosing strategy

Scancell Holdings PLC shares rose 6% after initiating patient dosing in a new arm of its Phase II melanoma trial for iSCIB1+ Immunobody, testing an intradermal delivery and faster dosing schedule in combination with checkpoint inhibitors. This development is significant as the first eight patients showed no major side effects, building on earlier trial data that reported an 84% disease control rate and 20% complete response. The company is also strategically spinning out its GlyMab antibody platform into Glymab Therapeutics, further sharpening its development focus.

Analysis

Scancell Holdings PLC is demonstrating tangible progress in its clinical development pipeline, triggering a 6% share price increase to 10.37p. The initiation of a new cohort in its Phase II SCOPE trial for the iSCIB1+ melanoma therapy is a key operational milestone. This new arm is strategically designed to optimize the treatment regimen by testing an intradermal delivery method and an accelerated dosing schedule in combination with checkpoint inhibitors. The initial safety signal is positive, with the first eight patients showing no significant side effects, which de-risks this new approach to a degree. This development builds on a strong foundation of prior efficacy data from the trial, which reported an 84% disease control rate and a 20% complete response rate. Further clarity on the pipeline's potential is expected shortly, with data from the first three cohorts due in July and preliminary results from the new arm by year-end. Concurrently, the company is sharpening its corporate strategy by planning to spin out its GlyMab antibody platform, a move intended to enhance developmental focus and potentially unlock shareholder value.

Key Decisions for Investors

• Investors should monitor the upcoming clinical trial data releases in July and by year-end, as these are significant near-term catalysts that could materially impact the company's valuation.
• The planned spin-out of the GlyMab platform warrants close attention, as this corporate restructuring could unlock value but also fundamentally changes the company's asset profile.
• While the initial safety data for the new dosing strategy is encouraging, investors should remain cognizant of the inherent risks of clinical-stage biotechnology, as the positive outcome is based on a small patient sample and is not yet confirmed by broader efficacy data.